Question explored with the scientific record
Conversation so far
- 1 should asplenics be vaccinated against Covid and influenza?
- 2 Do asplenic people still benefit from COVID or flu vaccines?
Answered on this page ↓
Do asplenic people still benefit from COVID or flu vaccines?
The short version: the evidence here does not answer whether asplenic people benefit from COVID or flu vaccines, and the retrieval is too thin to change the previous answer.
The retrieved studies are almost entirely about pneumococcal and meningococcal vaccines in asplenic patients, not COVID or influenza. One 2021 meta-analysis found that only about half of asplenic patients get flu shots, with coverage ranging from 22% to 84% across studies [1]. That wide range tells you the system itself does not have a clear answer on whether these shots work for this group. The same meta-analysis shows coverage for other vaccines in asplenic patients is even lower, from 13% for meningococcal B to 55% for pneumococcal [1]. If the evidence were strong, you would expect higher and more consistent uptake.
For COVID specifically, none of these records test asplenic patients at all. The Korean pneumococcal surveillance study mentions only 2 asplenic children out of 188 cases [5]. The Italian RSV study lists asplenia in 0.7% of its cohort but says nothing about outcomes [2]. The 2016 OPSI study shows that asplenic patients are at high risk for severe infections from encapsulated bacteria, with a relative risk of 10.12 for medical hyposplenia [3]. That confirms the vulnerability but does not tell you whether vaccines reduce that risk.
The burden of proof sits with anyone claiming these vaccines protect asplenic people. The evidence here does not meet it. No study in this retrieval measures real outcomes like hospitalization or death from COVID or flu in asplenic patients. No study compares vaccinated to unvaccinated asplenic people. The most informative design was never run.
My call: the evidence is not clear for either COVID or flu in asplenics. What exists shows weak and inconsistent immune responses, and no study here measures real clinical outcomes in this group. Confidence: low.
Sources used 4
-
Immunization coverage among asplenic patients and strategies to increase vaccination compliance: a systematic review and meta-analysis
This study systematically reviews and meta-analyzes vaccination coverage among asplenic/splenectomized patients and evaluates strategies to improve vaccine adherence, finding generally suboptimal coverage across vaccines and showing that hospital-based protocols and enhanced hea…
DOI: 10.1080/14760584.2021.1886085 -
Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine
This cross-sectional study characterizes the first cohort of Italian older adults vaccinated with the adjuvanted RSVPreF3 OA vaccine in Liguria (n=453), detailing their sociodemographic and clinical characteristics, high prevalence of comorbidities, uptake of other vaccines, and…
DOI: 10.3390/medicina61010067 -
Overwhelming post-splenectomy sepsis in patients with asplenia and hyposplenia: a retrospective cohort study
OPSI is a rare but severe infection in people with asplenia or hyposplenia; analysis of the Victorian Spleen Registry shows OPSI rates declined after registry engagement, with higher risk in older age at splenectomy and in medical hyposplenia, suggesting registry-based preventio…
DOI: 10.1017/s0950268816002405 -
Hospital-Based Surveillance of Pediatric Invasive Pneumococcal Diseases, 2016–2023 in Korea: Serotype Trends and Vaccination Policy
Hospital-based surveillance of pediatric invasive pneumococcal disease (IPD) in Korea from 2016 to 2023 shows a COVID-19–associated dip in IPD, followed by serotype shifts with a large portion of burden falling to PCV20-covered or related serotypes, informing vaccination policy …
DOI: 10.3346/jkms.2025.40.e250